



Icahn School of Medicine at Mount Sinai
 Mount Sinai Beth Israel
 Mount Sinai Brooklyn
 The Mount Sinai Hospital
 Mount Sinai Queens
 New York Eye and Ear Infirmary
 of Mount Sinai
 Mount Sinai St. Luke's
 Mount Sinai West

**Program for the Protection
 of Human Subjects**
Institutional Review Boards
 Mount Sinai Health System
 One Gustave L. Levy Place, Box 1081
 New York, NY 10029-6574
 T 212-824-8200
 F 212-876-6789
 irb@mssm.edu
 icahn.mssm.edu/pphs

APPROVAL OF RESEARCH

Date: 8/18/2017

To: Richard Whelan, MD (Rwhelan@chpnet.org)

On **8/15/2017**, an Institutional Review Board of the Mount Sinai School of Medicine, in accordance with Mount Sinai's Federal Wide Assurances (FWA#00005656, FWA#00005651) to the Department of Health and Human Services approved the following human subject research from **8/15/2017** until **8/6/2018** inclusive:

Type of Review:	Continuing Request for Approval
Project Title:	Tumor, perioperative blood sample, and clinical data banking for cancer, physiology, immunology, and other research studies
Investigator:	Richard Whelan, MD (Dept: SU - Surgery)
Project Information:	HS#: 15-00817 GCO#1: 16-2619(0001) ISMMS
Sites:	Mount Sinai West
IND or IDE (if any):	No INDs;No IDEs;
Submission Details (if any):	Melissa Alvarez-Downing, Erica Pettke, and Abhinit Shah have been removed from study personnel. Carl Winkler has been added to study personnel.

Between 6/20/2018 and 6/25/2018, or within 30 days prior to study close, whichever is earlier, you are to submit a completed FORM HRP-212: Continuing/Final Review Progress Report and required attachments, in order to request continuing IRB approval or study closure. If IRB continuing review approval is not granted before the expiration date of **8/6/2018**, IRB approval of this research expires on that date.

□□□□□□ The IRB has determined that this research involves GREATER THAN minimal risk. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests (45CFR.46.102; 21CFR50.3k).

□□□□□□ IRB re-approval was not obtained prior to the expiration date. It must be noted that if any subjects were entered or research procedures conducted between 8/6/2017 and the final approval date of this renewal, the research was unauthorized by the IRB.

In conducting this research you are required to follow the requirements listed in

the **Investigator Manual**. If stamped approved consent forms are attached, use copies of these forms to document consent. IRB approval does not constitute or imply institutional support for the conduct of this research. Additionally, all required local committee approvals at each **research affiliate** site must be obtained prior to initiation.

cc: Study Contact(s): Xiaohong (Peter) Yan (peter.yan@mountsinai.org)

 Mount Sinai	Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel Mount Sinai Brooklyn The Mount Sinai Hospital Mount Sinai Queens New York Eye and Ear Infirmary of Mount Sinai Mount Sinai St. Luke's Mount Sinai West	Program for the Protection of Human Subjects <i>Institutional Review Boards</i> Mount Sinai Health System One Gustave L. Levy Place, Box 1081 New York, NY 10029-6574 T 212-824-8200 F 212-876-6789 irb@mssm.edu icahn.mssm.edu/pphs
---	--	---

APPROVAL OF RESEARCH

Date: 11/3/2017

To: **Richard Whelan, MD** (rwhelan@chpnet.org)

On **10/31/2017**, an Institutional Review Board of the Mount Sinai School of Medicine, in accordance with Mount Sinai's Federal Wide Assurances (FWA#00005656, FWA#00005651) to the Department of Health and Human Services approved the following human subject research from **10/31/2017** until **10/10/2018** inclusive:

Type of Review:	Continuing Request for Approval
Project Title:	The influence of wound healing and negative pressure wound therapy on local and systemic angiogenic factors
Investigator:	Richard Whelan, MD (Dept: SU - Surgery)
Project Information:	HS#: 16-01019 GCO#1: 16-1863(0001) Icahn School of Medicine at Mount Sinai
Sites:	Mount Sinai
IND or IDE (if any):	No INDs;No IDEs;
Submission Details (if any):	None

Between 8/24/2018 and 8/29/2018, or within 30 days prior to study close, whichever is earlier, you are to submit a completed FORM HRP-212: Continuing/Final Review Progress Report and required attachments, in order to request continuing IRB approval or study closure. If IRB continuing review approval is not granted before the expiration date of 10/10/2018, IRB approval of this research expires on that date.

□□□□□□ The IRB has determined that this research involves GREATER THAN minimal risk. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests (45CFR.46.102; 21CFR50.3k).

□□□□□□ IRB re-approval was not obtained prior to the expiration date. It must be noted that if

any subjects were entered or research procedures conducted between 10/10/2017 and the final approval date of this renewal, the research was unauthorized by the IRB.

In conducting this research you are required to follow the requirements listed in the **Investigator Manual**. If stamped approved consent forms are attached, use copies of these forms to document consent. IRB approval does not constitute or imply institutional support for the conduct of this research.